Biovica the developer of the DiviTum™ cell proliferation assay
Biovica has developed a simple blood test, DiviTum™, a highly sensitive Thymidine Kinase assay for measuring cell proliferation. One of the most fundamental characteristics of cancer is uncontrolled and increased cell growth. DiviTum™ therefore enables reliable detection, prediction and therapy monitoring of cancer with unprecedented sensitivity and precision.
- Will the treatment work or not?
- Is the treatment working or not?
Those are key questions where DiviTum™ have the possibility to make a significant contribution of major value to clinicians and pharma research companies.
The DiviTum™ technology is easy and efficient:
- DiviTum measures whats fundamental in cancer; cell proliferation rate.
- DiviTum requires only a small & simple blood sample (serum) for analysis.
- DiviTum is the most sensitive and precise test to measure cell proliferation in blood.
DiviTum™ in your clinical trial
DiviTum™ can accelerate your oncology drug development process and more efficiently evaluate your pipeline compounds. The DiviTum™ technology can increase the productivity of drug innovation and reduce R&D cost.
The DiviTum™ technology has demonstrated the ability to:
- Predict drug efficacy.
- Stratify patient populations in responders and non-responders.
- Improve evaluation and monitoring of therapy efficacy during treatment.